These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2340601)

  • 1. Biophysical inhibition of synthetic lung surfactants.
    Holm BA; Venkitaraman AR; Enhorning G; Notter RH
    Chem Phys Lipids; 1990 Feb; 52(3-4):243-50. PubMed ID: 2340601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
    Wang Z; Chang Y; Schwan AL; Notter RH
    Am J Respir Cell Mol Biol; 2007 Oct; 37(4):387-94. PubMed ID: 17556674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Hall SB; Venkitaraman AR; Whitsett JA; Holm BA; Notter RH
    Am Rev Respir Dis; 1992 Jan; 145(1):24-30. PubMed ID: 1731593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content of dipalmitoyl phosphatidylcholine in lung surfactant: ramifications for surface activity.
    Holm BA; Wang Z; Egan EA; Notter RH
    Pediatr Res; 1996 May; 39(5):805-11. PubMed ID: 8726232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
    Holm BA; Notter RH
    J Appl Physiol (1985); 1987 Oct; 63(4):1434-42. PubMed ID: 3693177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.
    Wang Z; Schwan AL; Lairson LL; O'Donnell JS; Byrne GF; Foye A; Holm BA; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2003 Sep; 285(3):L550-9. PubMed ID: 12902318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple mechanisms of lung surfactant inhibition.
    Holm BA; Wang Z; Notter RH
    Pediatr Res; 1999 Jul; 46(1):85-93. PubMed ID: 10400140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral cell wall lipids of Mycobacterium tuberculosis are inhibitory to surfactant function.
    Wang Z; Schwab U; Rhoades E; Chess PR; Russell DG; Notter RH
    Tuberculosis (Edinb); 2008 May; 88(3):178-86. PubMed ID: 18155644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Component-specific surface and physiological activity in bovine-derived lung surfactants.
    Notter RH; Wang Z; Egan EA; Holm BA
    Chem Phys Lipids; 2002 Jan; 114(1):21-34. PubMed ID: 11841823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro--comparison to natural surfactant.
    Seeger W; Thede C; Günther A; Grube C
    Biochim Biophys Acta; 1991 Jan; 1081(1):45-52. PubMed ID: 1991155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additivity of protein and nonprotein inhibitors of lung surfactant activity.
    Wang Z; Notter RH
    Am J Respir Crit Care Med; 1998 Jul; 158(1):28-35. PubMed ID: 9655703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Content-dependent activity of lung surfactant protein B in mixtures with lipids.
    Wang Z; Baatz JE; Holm BA; Notter RH
    Am J Physiol Lung Cell Mol Physiol; 2002 Nov; 283(5):L897-906. PubMed ID: 12376341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids.
    Notter RH; Gupta R; Schwan AL; Wang Z; Shkoor MG; Walther FJ
    PeerJ; 2016; 4():e2635. PubMed ID: 27812430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids.
    Turcotte JG; Lin WH; Pivarnik PE; Sacco AM; Shirali SS; Bermel MM; Lu Z; Notter RH
    Biochim Biophys Acta; 1991 Jun; 1084(1):1-12. PubMed ID: 2054372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary importance of zwitterionic over anionic phospholipids in the surface-active function of calf lung surfactant extract.
    Wang Z; Gurel O; Weinbach S; Notter RH
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1049-57. PubMed ID: 9351602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical activity of synthetic phospholipids combined with purified lung surfactant 6000 dalton apoprotein.
    Notter RH; Shapiro DL; Ohning B; Whitsett JA
    Chem Phys Lipids; 1987 Jun; 44(1):1-17. PubMed ID: 3607971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant.
    Yu SH; Possmayer F
    Biochim Biophys Acta; 1988 Aug; 961(3):337-50. PubMed ID: 3401500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles.
    Beck-Broichsitter M; Ruppert C; Schmehl T; Günther A; Seeger W
    Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):474-81. PubMed ID: 24184425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics.
    Hall SB; Lu RZ; Venkitaraman AR; Hyde RW; Notter RH
    J Appl Physiol (1985); 1992 May; 72(5):1708-16. PubMed ID: 1601776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An amphipathic alpha-helical decapeptide in phosphatidylcholine is an effective synthetic lung surfactant.
    McLean LR; Lewis JE; Krstenansky JL; Hagaman KA; Cope AS; Olsen KF; Matthews ER; Uhrhammer DC; Owen TJ; Payne MH
    Am Rev Respir Dis; 1993 Feb; 147(2):462-5. PubMed ID: 8430972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.